Active Biotech : Active Biotech raises SEK 270 million through a directed new issue to Investor

Active Biotech : Active Biotech raises SEK 270 million through a directed new
                              issue to Investor

Lund, Sweden, March 6, 2013 - Active Biotech (NASDAQ OMX NORDIC: ACTI) today
announces that the company's Board of Directors has, based on the 2012 annual
general meeting's authorization, resolved to issue in total 6,000,000 new
shares in Active Biotech to Investor AB (publ).

The shares are issued at a subscription price of SEK 45 per share, providing
the company with in total approximately SEK 270 million after transaction
costs. The closing price for the Active Biotech share on NASDAQ OMX Stockholm
on March 5, 2013 was SEK 48.80.

The issue proceeds are intended to be used to strengthen Active Biotech's
capital base and to enable the continued development and value-growth of the
project portfolio, of which TASQ is financed under the partner agreement with
Ipsen Pharma, whilst 57-57, ANYARA and ISI are managed and financed on a
proprietary basis. The development of laquinimod and RhuDex are managed and
financed by partners. The new issue also strengthens Active Biotech's position
in discussions with potential partners.

The Board considers it being beneficial for the company and the shareholders
to broaden the shareholder base and to take advantage of the opportunity to
raise capital on favourable terms for the company from a strong and well
renowned investor. The Board believes that the new issue, which in light of
the above is made with deviation from the shareholders' pre-emptive rights,
will promote the creation of value for all shareholders of the company. Active
Biotech's two largest shareholders MGA Holding AB and Nordstjernan AB, and
East Bay AB, with a joint holding of votes and shares of approximately 44
percent, have stated that they support the new issue.

Tomas Leanderson, CEO of Active Biotech comments: "I am very pleased to see
that Active Biotech's project portfolio has obtained additional financing from
Investor. Active Biotech's portfolio has now matured and, accordingly, our
focus over the next 18-month period will be on finding suitable partners and
partnering structures for each project. A strong financial position is a
prerequisite in order to succeed with this activity in an optimal way."

Through the new issue, the number of shares in Active Biotech will increase by
6,000,000 from 68,923,582 to 74,923,582 and the share capital will increase by
SEK 22,616,055.93 from SEK 259,796,597.53 to SEK 282,412,653.46. Investor's
holding will correspond to approximately 8 percent of the shares and votes in
Active Biotech.

Lund, March 6, 2013
Active Biotech AB (publ)

For further information, please contact:
Tomas Leanderson, CEO
Tel: +46 (0)46 19 20 95

Hans Kolam, CFO
Tel: +46 (0)46 19 20 44

Active Biotech AB (NASDAQ  OMX NORDIC: ACTI) is  a biotechnology company  with 
focus on  autoimmune/inflammatory diseases  and  cancer. Projects  in  pivotal 
phase are  laquinimod,  an  orally administered  small  molecule  with  unique 
immunomodulatory properties for the treatment of multiple sclerosis, TASQ  for 
prostate cancer and ANYARA primarily for  the treatment of renal cell  cancer. 
In addition, laquinimod is in Phase II development for Crohn's and Lupus.  The 
company also has one  additional project in  clinical development, the  orally 
administered   compound   57-57   for   Systemic   Sclerosis.   Please   visit for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This information
was provided to the media for publication 8:30 a.m. CET on March 6, 2013.

Active Biotech raises SEK 270 million through a directed new issue to


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Active Biotech via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.